NO985480L - Anvendelse av inhibitorer av en cellulµr Na+/H+- veksler (NHE) for fremstilling av et medikament for normalisering av serumlipider - Google Patents

Anvendelse av inhibitorer av en cellulµr Na+/H+- veksler (NHE) for fremstilling av et medikament for normalisering av serumlipider

Info

Publication number
NO985480L
NO985480L NO985480A NO985480A NO985480L NO 985480 L NO985480 L NO 985480L NO 985480 A NO985480 A NO 985480A NO 985480 A NO985480 A NO 985480A NO 985480 L NO985480 L NO 985480L
Authority
NO
Norway
Prior art keywords
nhe
normalization
inhibitors
exchanger
cellular
Prior art date
Application number
NO985480A
Other languages
English (en)
Norwegian (no)
Other versions
NO985480D0 (no
Inventor
Hans Jochen Lang
Hans-Willi Jansen
Jan-Robert Schwark
Heinz-Werner Kleemann
Oliver Jung
Hans-Ludwig Schofer
Wolfgang Linz
Werner Kramer
Lkens Bernward Sch
Eugen Falk
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19712636A external-priority patent/DE19712636A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO985480D0 publication Critical patent/NO985480D0/no
Publication of NO985480L publication Critical patent/NO985480L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
NO985480A 1996-06-03 1998-11-24 Anvendelse av inhibitorer av en cellulµr Na+/H+- veksler (NHE) for fremstilling av et medikament for normalisering av serumlipider NO985480L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19622222A DE19622222A1 (de) 1996-06-03 1996-06-03 Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
DE19712636A DE19712636A1 (de) 1997-03-26 1997-03-26 Verwendung von Inhibitoren des zellulären Na+/H+Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
PCT/EP1997/002548 WO1997046226A2 (de) 1996-06-03 1997-05-20 VERWENDUNG VON INHIBITOREN DES ZELLULÄREN Na+/H+-EXCHANGERS (NHE) ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR NORMALISIERUNG DER SERUMLIPIDE

Publications (2)

Publication Number Publication Date
NO985480D0 NO985480D0 (no) 1998-11-24
NO985480L true NO985480L (no) 1999-01-28

Family

ID=26026256

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985480A NO985480L (no) 1996-06-03 1998-11-24 Anvendelse av inhibitorer av en cellulµr Na+/H+- veksler (NHE) for fremstilling av et medikament for normalisering av serumlipider

Country Status (23)

Country Link
EP (1) EP0918515B1 (pt)
JP (1) JP4527811B2 (pt)
KR (1) KR100511711B1 (pt)
CN (1) CN1221339A (pt)
AR (1) AR007353A1 (pt)
AT (1) ATE293965T1 (pt)
AU (1) AU722166B2 (pt)
BR (1) BR9709516A (pt)
CA (1) CA2257299A1 (pt)
DE (2) DE19622222A1 (pt)
DK (1) DK0918515T3 (pt)
ES (1) ES2241049T3 (pt)
IL (1) IL126935A0 (pt)
NO (1) NO985480L (pt)
NZ (1) NZ333095A (pt)
PL (1) PL189950B1 (pt)
PT (1) PT918515E (pt)
RU (1) RU2211032C2 (pt)
SI (1) SI0918515T1 (pt)
SK (1) SK165898A3 (pt)
TR (1) TR199802505T2 (pt)
WO (1) WO1997046226A2 (pt)
ZA (1) ZA974828B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011059A (en) * 1997-12-24 2000-01-04 Bristol-Myers Squibb Company Acyl guanidine sodium/proton exchange inhibitors and method
US6160134A (en) * 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
DE19859727A1 (de) * 1998-12-23 2000-06-29 Aventis Pharma Gmbh Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung
JP2002542291A (ja) 1999-04-23 2002-12-10 ブリストル−マイヤーズ スクイブ カンパニー ジ環式アシルグアニジン・ナトリウム／プロトン交換抑制剤および方法
DE19945302A1 (de) * 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenylderivate als NHE-3-Inhibitoren
US6423705B1 (en) 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
AU2002348276A1 (en) 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US7230007B2 (en) 2003-06-12 2007-06-12 Sanofi-Aventis Deutschland Gmbh Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
FR2856062B1 (fr) * 2003-06-12 2005-11-11 Aventis Pharma Sa Derives 3-guanidinocarbonyl-heterocycle, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
CA2529949C (en) * 2003-06-26 2013-08-06 Biotron Limited Antiviral compounds and methods
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7220859B2 (en) 2005-01-12 2007-05-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
EP1846410B1 (en) 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
AU2010229653A1 (en) 2009-03-27 2011-10-20 Astrazeneca Ab Methods for preventing major adverse cardiovascular events with DPP-IV inhibitors
US20130045992A1 (en) 2010-01-28 2013-02-21 President And Fellows Of Harvard College Compositions and Methods for Enhancing Proteasome Activity
TR201906779T4 (tr) 2011-05-12 2019-05-21 Proteostasis Therapeutics Inc Proteostaz regülatörleri.
US9586900B2 (en) 2012-09-05 2017-03-07 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
US9499482B2 (en) 2012-09-05 2016-11-22 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
EA202190226A1 (ru) 2018-07-19 2021-06-16 Астразенека Аб СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110817A (en) * 1988-10-21 1992-05-05 Beyer Jr Karl H Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
US4920123A (en) * 1988-10-21 1990-04-24 Beyer Jr Karl H Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
AU7316591A (en) * 1990-02-28 1991-09-18 Upjohn Company, The Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
EP0612723B1 (de) * 1993-02-20 1997-08-27 Hoechst Aktiengesellschaft Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, als Inhibitoren des zellulären Na+/H+-Austauschs oder als Diagnostikum sowie sie enthaltendes Medikament
DE4318658A1 (de) * 1993-06-04 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4325822A1 (de) * 1993-07-31 1995-02-02 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
IL114670A0 (en) * 1994-08-05 1995-11-27 Fujisawa Pharmaceutical Co Guanidine derivatives pharmaceutical compositions containing the same and processes for the preparation thereof

Also Published As

Publication number Publication date
AU2957697A (en) 1998-01-05
ES2241049T3 (es) 2005-10-16
SI0918515T1 (sl) 2005-12-31
IL126935A0 (en) 1999-09-22
PL189950B1 (pl) 2005-10-31
ZA974828B (en) 1997-12-03
ATE293965T1 (de) 2005-05-15
PL330412A1 (en) 1999-05-10
EP0918515B1 (de) 2005-04-27
WO1997046226A2 (de) 1997-12-11
EP0918515A2 (de) 1999-06-02
PT918515E (pt) 2005-06-30
CA2257299A1 (en) 1997-12-11
NO985480D0 (no) 1998-11-24
JP4527811B2 (ja) 2010-08-18
RU2211032C2 (ru) 2003-08-27
DE19622222A1 (de) 1997-12-04
JP2000506906A (ja) 2000-06-06
DE59712287D1 (de) 2005-06-02
KR100511711B1 (ko) 2005-12-26
DK0918515T3 (da) 2005-08-15
CN1221339A (zh) 1999-06-30
SK165898A3 (en) 1999-05-07
BR9709516A (pt) 1999-08-10
TR199802505T2 (xx) 1999-04-21
NZ333095A (en) 2000-08-25
WO1997046226A3 (de) 1998-03-05
AR007353A1 (es) 1999-10-27
AU722166B2 (en) 2000-07-20
KR20000016240A (ko) 2000-03-25

Similar Documents

Publication Publication Date Title
NO985480L (no) Anvendelse av inhibitorer av en cellulµr Na+/H+- veksler (NHE) for fremstilling av et medikament for normalisering av serumlipider
MX173362B (es) Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
EE9700313A (et) Radiofarmatseutiliste ühendite valmistamise stabiilsed reagendid
DE69525148D1 (de) Pharmazeutische formulierung
DK0783302T3 (da) Lægemidler
EP0740545A4 (en) BASE FOR PHARMACEUTICAL OINTMENT
KR960016892A (ko) 약제의 신독성 경감제
KR970707115A (ko) 플루오로퀴놀론의 물리적으로 안정한 신규한 고체 형태(a new physically stable solid form of a fluoroquinolone)
MX14533A (es) Procedimiento para la preparacion de compuestos farmaceuticos
PT983249E (pt) Procesos e intermediarios para a preparacao de derivados de indazole substituidos
IT1273514B (it) Procedimento per la preparazione di un gel micro-mesoporoso
BR8802893A (pt) Sistema de descarga para compressor hermetico
FI973230A (fi) Uusi farmaseuttinen formulaatio
EE200000401A (et) Farmatseutilise preparaadi valmistamismeetod
DK37589A (da) Farmaceutisk praeparat for 4-aroylimidazol-2-oner
HUP0001879A3 (en) Use of inhibitors of the cellular na+/h+ exchanger (nhe) for preparing a medicament for normalizing serum lipids
BR9506663A (pt) Derivados do ácido hidroxâmico
BR8805020A (pt) Descarga para compressor rotativo
SE9404195D0 (sv) New pharmaceutical formulation
BR8802019A (pt) Conexao para conducao de fluidos
NO962816D0 (no) Farmasöytiske forbindelser
BR6901548U (pt) Suporte anti-vibracoes para cardan
ES288057Y (es) Estructura para la compartimentacion interior de un habita- culo
BR6501734U (pt) Crioextrator para cirurgia de catarata
FIU940283U0 (fi) Sjaelvbevattning utnyttjande kruksystem

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application